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ABSTRACT 
SOCIAL WORK 
HENDERSON, PHEBEE VUN B.S.Georgia State University, 1986 
A SINGLE SYSTEMS STUDY EXAMINING THE EFFECTS OF INTEGRATING 
PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL TREATMENT TO INCREASE 
THE QUALITY OF LIFE FOR SCHIZOPHRENICS 
Advisor: Sandra Foster, Ph. D. 
Thesis dated: March 27, 1997 
The purpose of this study was to examine the 
effectiveness of an integrative treatment (antipsychotic with 
psychosocial interventions) approach in an attempt to 
decrease or alleviate the negative symptoms associated with 
schizophrenia. Drug therapy has long been the usual mode of 
treatment used for this pervasive illness, but has had little 
effect on the cognitive and social deficits experienced by 
most who suffer from schizophrenia. 
A single system design was employed to determine the 
effect of the integrative treatment on a patient in Emory 
University's Research and Behavioral Science Program. 
The study showed that there was an increase in the 
Quality of Life for the individual administered 
psychopharmacologic treatment in conjunction with 
psychosocial interventions. 
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Statement of the Problem 
Schizophrenia is a most complex and frustrating disease. 
Even with all the research that has been conducted, many 
gaps are still present in the understanding of this illness. 
Schizophrenia is not a rare disease. An estimated 2.8 
million Americans are affected by the disease; almost 1 in 
every 100. Schizophrenia is the most common of the 
psychoses, in which a person lacks insight and has difficulty 
meeting the demands of daily life and maintaining contact 
with reality. About half of the inpatients in U.S. mental 
hospitals are schizophrenic. According to Bleuler, 
schizophrenia has been conceptualized as a disease 
characterized by a chronic and progressively deteriorating 
illness course1 (Bleuler, 1911). But this pessimistic view 
is being challenged. Statistics indicate that approximately 
one-third of schizophrenic cases show a deteriorating course; 
one-third follow a fluctuating intermediate course; one-third 
show remission after an initial episode.2 Research data 
suggest that a substantial proportion of the schizophrenic 
population that suffers from this illness can be influenced 
by optimal psychopharmacologic and psychosocial treatment.3 
1 Erick Bleuler., Dementia Praecox for The Group of The Schizophrenias. (New York: 
International University Press 1911). 
2 G. Huber et al. Longitudinal Studies of Schizophrenic Patients. Schizophrenic Bulletin 
6, (1990): 592-605. 
3 Prendergast, P. J. Integration of Psychiatric Rehabilitation In the Long-Term 
Management of Schizophrenia. Canadian Journal of Psychiatry. Vol. 40, April (1995): 518-520. 
1 
The gap that has been recognized is that many 
researchers have focused on the theory of the combining 
2 
interventions (psychopharmacologic and psychosocial), but few 
have actually given attention to the implementation of the 
combined treatment approach to evaluate its alleviating 
the symptoms associated with the diminished quality of life 
in schizophrenic patients.4 
Rationale of the Study 
Researchers are constantly in search of the miracle pill 
that will end all the delusions and hallucinations associated 
with schizophrenia. But, there is no quick fix for the 
cognitive and social deficits that rapidly infringe upon the 
quality of life of the patient. For the individuals affected 
to receive an optimal level of care, community mental health, 
hospitals, families and private psychiatrist must employ 
psychosocial as well as pharmacologic treatment approaches. 
Many of these patients can lead productive lives if 
clinicians would go the extra mile. Greater care can be 
given to provide patients with better survival skills thereby 
enriching the quality of their lives. By ignoring more 
complex treatment the individuals will be as once believed by 
Bleuler (1911), on a course of deterioration. Though there 
is no cure and no known prevention, much testimony has been 
given about influencing the course of this illness. There is 
no new knowledge that psychopharmacological treatment is 
effective for treating acute symptoms and reducing 
4 Nasrallah, H.A., Handbook of Schizophrenia: Psychosocial Treatment of Schizophrenia. 
(New York: Elsevier Science Publishing Co. Inc 1990). 
3 
vulnerability to relapse, but to adequately address all the 
deficits associated or diminished by the illness, 
psychosocial interventions are needed to help prepare persons 
with schizophrenia to cope with their illness, strive for 
greater self-sufficiency, and achieve a better quality of 
life. 
With an increase of information in this area, it is 
necessary that the information be synthesized to inform 
clinicians of the most efficacious treatment. The focus of 
current treatment approaches should address the complexity of 
the illness by interacting drug and psychosocial treatments 
to deal with the chronically disabled person. Schizophrenia 
can be viewed like a chronic medical condition, such as 
diabetes, but is usually more complex.5 Lack of insight as 
is related to the characteristics of the illness and 
medication on the part of the patient, often lead to poor 
treatment compliance and eventually to relapse. 
Subsequently, schizophrenia is exquisitely sensitive to 
psychosocial factors, requiring support that is more 
comprehensive, continuous, and individually intensive than 
most chronic medical conditions. The schizophrenic patient 
customarily requires a system of care, the foundation of 
which includes both pharmacologic and psychosocial treatment 
approaches. Without this study of these two treatment 
approaches, information may not be available that could have 
great impact on the overall treatment of this illness. 
5 Leonard Stein. A System Approach to Reducing Relapse in Schizophrenia. Journal of 
Clinical Psychiatry. 54(1993): 7-12. 
4 
Purpose of Study 
The purpose of this study is to examine the effectiveness of 
integrating psychopharmacologic and psychosocial treatment to 
increase the quality of life for a schizophrenic patient. 
CHAPTER 2 
LITERATURE REVIEW 
Within this section articles will be reviewed that have 
a direct impact on this study as they relate to increasing 
the quality of life for a schizophrenic patient. First, the 
prevalence of the illness in the general population will be 
restated. Then,an overview of the various interventions used, 
will be observed. Lastly, interventions intended to be 
employed for this study will be reviewed in detail. 
Prevalence 
Schizophrenia is a serious mental disorder that affects 
approximately two million Americans. Although the prevalence 
of the disorder is minute related to major affective 
disorders and some chronic medical conditions, the economic 
and social impact is substantial. The costs associated with 
loss of productivity and treatment are estimated at $30 
billion annually.1 Excessive mortality is associated with 
this illness, with a 20% shorter life expectancy compared 
with the general population and a 10% suicide rate.2 
Significant progress has been made over the past 30 years 
in the pharmacological treatment of the symptoms of this 
disorder, however, schizophrenia remains a chronic condition 
subject to relapse and serious functional limitations for 
many of those who have the disorder. Although a cure is not 
currently available, individuals who receive adequate 
psychiatric care for their illness may experience less 
frequent clinical exacerbations of their symptoms and may be 
1 AlanBreier. The New Pharmacotherapy of Schizophrenia. (Washington, D.C.: American 




able to enjoy a higher quality of life. 
Lack of understanding surrounding the nature of 
schizophrenia has stimulated great debates and controversies 
among those who seek to help its victims. It inflicts much 
shame, guilt and unnecessary suffering among persons and 
families who are affected by it. Though significant strides 
have been made in the well intended pharmacological 
treatment, reform for the care of patients with schizophrenia 
is still before us. 
Factors Related to Quality of Life in the 
Schizophrenic Population 
It has been stated and restated that schizophrenia 
effects the patient at all levels of his existence. The 
models of treatment should be as broad as the illness. 
Schizophrenic episodes that impede upon the quality of life 
are multiply determined: they are caused by the interaction 
of a wide range of environmental, behavioral and biological 
factors. As a result of these interactional effects, it is 
doubtful that significant long-term therapeutic gains can be 
achieved by focusing on a single psychosocial factor 
associated with the source of the disease.3 
According to Sautter and McDermott, the most significant 
therapeutic gains have been reported with family management 
techniques that impact upon a range of factors that influence 
relapse. These programs seek to educate the family and teach 
them coping skills in addition to changing attitudes and 
3 Fredric Sautter and Barbara McDermott, Current Concepts in The Psychosocial 
Management of Schizophrenia.Psychiatric Medicine 8/1(19901 125-141 
directly modifying patient-relative interactions. Over the 
last twenty years, there has been a dramatic increase in 
research designed to guide the development of family 
treatment for schizophrenia.4 Research has shown that 
schizophrenics show more favorable levels of adjustment when 
discharged to the homes of distant relatives as opposed to 
when they are returned to households with close relatives. 
These data suggest that the emotional response of key 
household members to the patient's disturbed behavior is of 
great prognostic significance. The program was designed 
specifically to lower the level of expressed emotion in the 
family as well as to reduce the amount of direct contact that 
takes place between the patient and high expressed 
emotion(EE) relatives. This approach would seemingly be 
advantageous for the patients that still live within their 
family structure; however, a vast majority of these patients 
are homeless or live in supervised housing or personal care 
facilities. 
If a group approach is to be applied it would be best 
suited for day treatment groups involving peer interaction as 
is done with social skills training. Social skills training 
is a form of psychotherapy that is formed by behavioral and 
learning theories.5 This approach is of the most highly 
structured form of psychosocial therapy for schizophrenic 
individuals. According to Vaccaro and Alexander (1993), the 
4 Ibid. Sautter and McDermott, Current Concepts in The Psychosocial Management of 
Schizophrenia. 125-141. 
5 Jerome Vaccaro, Alexander Young et al., Community-Based Care of Individuals With 
Schizophrenia: Combining Psychosocial and Pharmacologic Therapies. Psychiatric Clinics of 
North America 16/2 (1993): 387-399. 
8 
goals are explicitly stated, (e.g., to teach medication 
management or conversational skills), Sessions are planned in 
advance, procedures such as role playing and structured 
problem solving are employed and homework exercises are used 
to enhance generalization of skill usage to other life areas. 
Group practices are most effective, as they provide 
opportunities for vicarious learning and a built in "buddy 
system" for completing homework. 
Controlled studies have yielded convergent findings as 
to the efficacy of social skill training. Findings concluded 
that individuals learn the skills taught, retain this 
knowledge and skill over extended periods, and that their 
relapse rates are reduced, particularly when combined with 
sound pharmacotherapy. Moreover to such highly perspective 
approaches, there are less structured approaches to social 
skills training that have been characterized in literature.6 
Liberman and Meuser (1986) articulated an approach in which 
the principles and practice of social skills training are 
employed to teach participants the problem-solving skills 
they need to negotiate daily living.7 This "Successful 
Living Group" format is often used to set treatment and 
rehabilitation goals.8 
In addition to the skill training and reduction of 
expressed emotion through family management, special 
vocational programs are alternatives that are often ignored 
6 Ibid. Sautter, and McDermott, Current Concepts in The Psychosocial Management of 
Schizophrenia. 125-141. 
7 Ibid. 
8H. A. Nasrallah, Handbook of Schizophrenia: Psychosocial Treatment of Schizophrenia. 
New York: Elsier Science Publishing Co., Inc., 1990), 300. 
9 
or relegated to obscurity in mental health systems.9 Early 
approaches stressed hospital based work programs as the main 
stays of intervention.10 This sheltered approach was 
hindered because it was seen as pathways to "dead-end" jobs, 
which offered no future and taught few marketable work 
skills. 
In the 1960's, the community mental health movement set 
the necessary conditions for transition from hospital-based 
vocational programs into more mainstream activities. 
However, this potential was never realized and transitional 
employment programs, evolved independently and often without 
much input from mental health or rehabilitation 
professionals. Consequently, we have entered a new phase of 
vocational rehabilitation marked by the emergence of the 
supported employment movement. The federally sponsored 
employment initiative emerged from the understanding that 
individuals with psychiatric disabilities require ongoing 
training services that are necessary to maintain employment 
once competitive employment has been secured. Patients are 
placed in settings of employment and then trained for the 
position. In its fully applied form, individuals are offered 
services indefinitely and "job coaches" visit them at their 
workplaces to help them learn and retain the technical, 
interpersonal, and problem-solving skills they need to 
sustain employment. This allows the patients, not only 
financial remuneration but is also a normalizing experience, 
9 Ibid. Nasrallah, Handbook of Schizophrenia: Psychosocial Treatment of Schizophrenia. 
300. 
10H. A. Nasrallah, Handbook of Schizophrenia: Psychosocial Treatment of Schizophrenia- 
New York: Elsier Science Publishing Co., Inc., 1990), 300.id. 
10 
allowing individuals to participate socially, and may promote 
self esteem and quality of life. Furthermore, the vast 
majority of persons with severe mental illnesses identify 
paid employment as one of their goals.11 
With all that has been discussed about psychosocial 
interventions in the treatment of this pervasive illness, 
this modality is still a relatively new approach. But since 
the 1950's conventional antipsychotic medication has been the 
norm for treatment whether effective or not. In relation to 
the interactive effects of psychosocial and 
psychopharmacologic treatment, the most common current 
belief, one often tacitly accepted by pharmaceutical 
advertisements, is that medication makes patients more 
receptive to psychotherapeutic efforts.12 The latter, 
pharmacotherapy is the treatment of choice because of its 
structure and reduced tendencies to cause lasting 
extrapyramidal side effects. These are drugs marketed since 
1990 or used experimentally to treat schizophrenia. 
Psychopharmacologic and Psychosocial Approaches Used 
to Enhance the Quality of Life 
for Schizophrenics 
The first era in the modern pharmacotherapy of 
schizophrenia began in the early 1950's with serendipitous 
discovery followed by confirmation that chlorpromazine was an 
11 Anthony Lehman. Vocational Rehabilitation in Schizophrenia. Schizophrenic Bulletin 
6, (1990) 645-655. 
12lbid. Nasrallah, Handbook of Schizophrenia: Psychosocial Treatment of Schizophrenia. 
300. 
11 
effective antipsychotic agent.13 Chlorpromazine and the 
neuroleptics that followed offered unequivocal clinical 
improvements for the majority of patients with schizophrenia. 
The use of these compounds dramatically changed the clinical 
arena of this illness. However, neuroleptic drugs rarely 
result in complete symptom remission and the patients return 
to premobid levels of functioning. Due to the complexity of 
the illness, there is a substantial number of patients with 
schizophrenia that receive little or no benefit from these 
drugs at all.14 Moreover, their side effects, such as extra 
pyramidal symptoms and tardive dyskinesia, contributes to 
personal discomfort, noncompliance, physical disfigurement, 
and disability. With all the side effects attributed to the 
psychopharmacologic treatment of the past era, it can be 
easily said that since the introduction of chlorpromazine, 
there has been no significant breakthrough in drug treatment 
until recently.15 
Clozapine represents the first major advance in the 
pharmacological treatment of schizophrenia since the 
introduction of antipsychotics. Studies have consistently 
supported its efficacy for reducing positive symptoms in 
acutely psychotic patients and in treatment-resistant 
patients, for preventing positive symptom exacerbations as a 
maintenance treatment, and for reducing symptoms of hostility 
13 Ibid. Breier. The New Pharmacotherapy of Schizophrenia. 
14 Patricia Higgins. Clozapine and The Treatment of Schizophrenia, Health and Social 
Work. Vol. 20, No 2. May 1995. 
15 Ibid. Breier. The New Pharmacotherapy of Schizophrenia. 
12 
and violence. There is evidence to suggest that clozapine 
may improve social and occupational functioning and quality 
of life and may reduce affective symptoms, hospitalization, 
secondary negative symptoms, and tardive dyskinesia.16 
Although clozapine has proven to be efficacious in the 
treatment of many patients living with schizophrenia, 
Clozapine is not without its dangers. A potentially lethal 
side effect, agranulocytosis, is possible. Though this is a 
very serious condition and could possibly lead to death if 
not detected early, it only effects 1-2% of patients treated 
with clozapine. 
Though clozapine is relatively new in use in the United 
States (marketed in 1990), it was developed in the 1960's. 
In the early 1970's, clinical trials established that 
clozapine was an effective antipsychotic drug.17 Further 
trials suggested that clozapine had a favorable clinical 
profile with no(extrapyramidal side-effects) EPS. In 1975, 
13 clozapine treated patients in Finland developed 
agranulocytosis, which resulted in eight deaths.18 
Consequently, interest in clozapine dramatically 
dropped, and the manufacturer and distributor, Sandoz 
considered eliminating clozapine. However, due to a small 
number of psychiatrists and patients' family members 
indicating that certain clozapine treated patients were 
deriving symptom relief that was far superior to what was 
16






achieved with previous antipsychotic drugs, clozapine was 
made available on a limited, compassionate-need basis for the 
most severely ill patients. 
In the ten years that followed, the use of clozapine 
slowly increased, particularly in Europe. The reports were 
conclusive in the efficacy compared with conventional 
neuroleptics in treatment-resistant patients with 
schizophrenia and did not produce EPS. In part, due to no 
promising alternative treatments being available for severely 
treatment-resistant patients with schizophrenia and because 
of the desperate plight of these patients, a multi-center 
trial of clozapine in the most severely ill, neuroleptic 
treatment resistant patients with schizophrenia was conducted 
in the United States. This study was known as Study 30. 
John Kane, Herbert Meltzer, and Gilbert Honigfeld were 
principally responsible for the design, implementation,and 
data analysis/reporting of Study 30.19 Sixteen inpatient 
treatment centers across the United States were selected to 
participate in the study and collectively enrolled 268 
patients with a diagnosis of schizophrenia. To meet criteria 
for enrollment patients had to have been unsuccessfully 
treated with at least three different conventional 
neuroleptic drugs. The research findings revealed that 
clozapine impacted negative and positive symptoms associated 
with schizophrenia. These results paved the road for Food 
and Drug Administration (FDA) approval of clozapine in the 
19
 Ibid.Breier. The New Pharmacotherapy of Schizophrenia. 
14 
United States. 
The marketing of clozapine gave much needed hope to 
professionals and family members of those plagued with 
schizophrenia. However, clozapine was very expensive and 
required weekly blood analysis. Since the marketing of 
clozapine, other atypical antipsychotics have been developed 
with some of the same benefits of clozapine without EPS and 
the most serious of all agranulocytosis. Risperidone was the 
next compound to receive FDA approval(1993), which was 
followed by sertindole and olanzapine. Seroquel is another 
compound with promise but is not available on the market, but 
is being used to treat patients experimentally. 
Though medication alleviates some of the positive 
symptoms (hallucinations and delusions) characterized by 
schizophrenia, in most instances, the negative symptoms (lack 
of effect, anhedonia, no motivation for life) and cognitive 
deficits go untouched.20 Numerous pharmaceutical companies 
as a part of their marketing, make promises of their 
particular compound being able to reduce positive 
symptomology and decrease hospitalization— thereby 
increasing the quality of life experienced by these 
individuals. Alleviating delusions and hallucinations are 
only part of what is needed to enhance the quality of life. 
Many social skills and cognitive abilities have been lost 
because of chronic disuse or may, as a result of poor 
premobid functioning, have never fully developed. Thus, 
20 John Kane and McGlashan. Treatment of Schizophrenia. The Lancet. 346: 820-825 
15 
psychosocial interventions are needed to help prepare persons 
with schizophrenia to cope with their illness, strive for 
greater self-sufficiency and achieve a better quality of 
life. 
Insufficient understanding of the potential therapeutic 
benefits and side effects of neuroleptic medications, and the 
failure to adhere to prescribed drug regimens are major 
contributors to relapse and rehospitalization of individuals 
with chronic schizophrenic disorders.21 Training in 
medication self-management is comprised of four skill areas: 
(1) Obtaining information about the benefits of antipsychotic 
medication: (2) knowing correct self-administration and 
evaluation of medication: (3) identifying side effects and 
(4) negotiating medication issues with health-care providers. 
Content approach of cognitive rehabilitation focuses on 
changing one's response to dysfunctional thoughts 
(delusions). Examples of this technique include modifying 
thoughts and beliefs associated with delusions and teaching 
ways to cope with auditory hallucinations (e.g. listening to 
music). There is a systematic method employed for treating 
residual psychotic symptoms, coined "coping strategy 
enhancement." Coping strategy enhancement is intended to 
build natural coping strategies for patients faced with 
residual symptoms. The intended use of this method is to 
help patients ground themselves in reality when actively 
21 Thad Eckman, R.P. Liberman, C.C. Phipps, and Karen Blair. Teaching Medication 
Management Skills to Schizophrenic Patients. Journal of clinical PsvchoDharmacoloav. Vol 10. 
No 1, 1990. 
16 
hallucinating or being bombarded with disorganized thought 
processes.22 
Because the schizophrenic patient requires the 
assistance of many different agencies to maintain societal 
living, continuity of care needs to be ensured. Many of 
these patients receive no care after hospitalization until, 
the next hospitalization. Case management services are 
available as a support system to assist patients in 
maneuvering through the mazes of the services they need to 
function in the community. 
Case managers have five basic functions—assessing, 
planning, linking, monitoring, and advocacy.23 Once the case 
manager has assessed a patient's strengths and deficits, they 
work with the patient to develop an individual service plan 
with goals, interventions and a time schedule for completion. 
When a patient is linked to specific programs of services, 
the case manager oversees the progress. When and if needed 
services are unavailable or deficient, the case manager 
advocates for the individual patient. These services have 
been found to be cost effective in decreasing the number of 
days patients spend in state hospitals. Many states are 
forcing case management upon patients that are frequently 
hospitalized. In addition to case management, day treatment 
programs help patients make transition from hospitals to 
22 Paul Liberman, Kim Muser, C.J. Wallace, et al. Training Skills in the Psychiatrically 
Disabled: Learning Coping and Competence. Schizophrenic Bulletin. Vol 12. No 14, 1986. 
23 Ibid. Sautter and McDermott, Current Concepts in The Psychosocial Management of 
Schizophrenia, 125-141. 
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independent living. These structured programs seek to 
prevent atrophy of their limited social skills and minimize 
the risk of relapse. The programs seek to give patients 
structured daily activity to prevent them from joining the 
ranks of the homeless or locking themselves away from 
meaningful social interaction. These programs offer a wide 
array of activities, ranging from: job readiness training, 
socialization and daily structure. 
In summary, this literature review has delineated the 
psychopharmacologic and psychosocial interventions that will 
be assessed to determine its therapeutic impact on the 
quality of life for the schizophrenic population. For the 
purpose of this study, a schizophrenic patient concurrently 
receiving an experimental antipsychotic and community 
psychosocial interventions, will be assessed to evaluate the 
effectiveness of a integrative treatment approach. 
Conceptual Framework 
Substantial evidence exists to support the concept of 
schizophrenia as a complex, multidimensional illness. For 
the illness to be successfully treated, there must be a 
skillful integration of therapeutic modalities used over a 
long term course. Clinicians and psychiatrist have long 
looked at treatment from an exclusively biomedical 
perspective, though the illness is recognized as a disorder 
of genetically predisposed neurophysiologic dysfunction. 
Incomplete concordance between monozygotic twins from studies 
suggests that important, nongenetic factors influence the 
18 
etiology, course and outcome of schizophrenia.24 
Consequently, many of these factors are nonbiological, social 
and psychological. Research has shown that 30-40% of the 
patients relapse in the first year following hospitalization, 
even when medication compliance is ensured.25 This validates 
the belief that psychological factors are a component in 
schizophrenia. 
If psychosocial and social factors are critical in the 
etiology, course and outcome of schizophrenia, it stands to 
reason that optimal outcome will be achieved through 
incorporating these factors into the treatment and management 
of the disorder.26 Although there is much evidence to 
support psychosocial therapies as an effective mode of 
treatment in improving the outcome in schizophrenia, numerous 
patients still go under treated with nonintergrated 
biomedical therapies. The usual treatment draws from a broad 
array of antipsychotic medications with varying degrees of 
efficacy and side effects.27 Even though there are numerous 
treatment 
strategies available, they often are uncoordinated addendum 
to psychotropic medication. Of the therapeutic approaches 
rendered in the treatment of schizophrenia, most are 
inadequately monitored and revised, overlooking the 
individual needs of the patients as they go through the 
24 Evan J. Collins and Heather Munroe-Blum. “Integrating Pharmacological and 
Psychosocial Treatments in Schizophrenia”, Contemporary Issues in the Treatment of 




different phases of illness, with the consequential effects 
being less than optimal treatment and outcome. 
19 
Combining psychosocial and pharmacological treatments to 
increase the quality of life is advocated as the optimal 
treatment for schizophrenia. If treatment is to be truly 
successful, the treatment objective would have to encompass 
both positive and negative symptoms. As previously stated, 
schizophrenia is a most complex and frustrating disease. The 
disease's psychotic symptoms such as dissociative thinking, 
hallucinations and delusions are dramatic, socially 
disruptive manifestations. These are just the positive 
symptoms which are usually treated to some degree with 
antipsychotics. The other side to the illness that 
medication does not effectively reach are the negative 
symptoms. Although they are less dramatic and more difficult 
to describe precisely than psychotic symptoms, the negative 
symptoms (functional deficits) are often the most enduring 
and crippling aspects of the diminished quality of life for 
the schizophrenic patient. The patients experience a 
weakening of emotional activity which form the mainstrings of 
volition. In connection with this, mental activity and 
instinct for life becomes mute. The result is emotional 
dullness and failure to thrive. To cover both negative and 
positive symptomology of the illness and enhance the rapidly 
diminishing quality of life, treatment needs to be 
multidimensional, treating the patients' psychological needs 
as well as social. 
Research Questions and Hypothesis 
Based on the forgoing conceptual framework, literature 
20 
review and general purpose of this study below is the 
research question and hypothesis. 
Question 
Does psychosocial and pharmacologic treatment have an effect 
on the quality of life for a schizophrenic patient? 
Hypothesis 
There is a positive relationship between psychosocial and 
psychopharmacologic treatment and the enhanced quality of 
life for schizophrenic. 
CHAPTER 3 
METHODOLOGY 
Research Design and Sample 
For the purpose of this study, a basic (AB) Single 
System Design was employed to evaluate the effectiveness of 
an integrated treatment approach (psychopharmacologic and 
psychosocial interventions). The selected subject was a 38 
year old white female who was concurrently receiving an 
experimental antipsychotic treatment at Emory University's 
Research and Behavioral Science Program while receiving 
psychosocial interventions at Skyland Trail Schizophrenic 
Residential Program. 
Measurement 
To measure the level of change in the individual's 
progression, several standardized assessments were utilized 
by the research team at Emory University. But for the 
purposes of this study, measuring quality of life, only the 
Positive and Negative Syndrome Scale (PANSS) and the Quality 
of Life Scale (See Appendix) were reviewed. 
The PANSS is a 30 item scale measuring general 
psychopathology, positive and negative symptoms of 
schizophrenia. The Quality of Life is a 21 item scale 
measuring deficit symptoms. 
Intervention Strategy and Plan 
The baseline was contrived from information obtained by 
clinician prior to the subject entering the research 
protocol. An assessment of the patient's current 
psychological and social functioning was ascertained prior to 
21 
the patient being administered the experimental 
antipsychotic, Seroquel. 
22 
The intervention phase consisted of seven data 
collection points on the Quality of Life Scale which was 
administered every 4 weeks and twelve data collection points 
on the PANSS which was administered every two weeks. To 
assess the overall progression and effectiveness of the 
intervention, the integrative approach, the baseline and the 
intervention phases were compared as shown in the graphs. 
Baseline Phase 
Prior to the subject receiving the experimental 
antipsychotic, Seroquel, a 1 week assessment was done to 
evaluate the overall level of functioning. The patient was 
assessed as having a diminished quality of life with both 
positive and negative symptomology. Patient was found to 
have a fourteen year history of schizophrenia with numerous 
psychiatric hospitalizations. Though she had been tried on 
several antipsychotics, she remained delusional and 
emotionally withdrawn. Patient complained of extrapyramidal 
side effects to most psychotropic medications which in the 
past led to noncompliance and exacerbation of symptoms and 
hospitalization. 
After a thorough examination, patient was administered 
the experimental compound, Seroquel in the dose of 25 mg BID 
(A.M and P.M). This was given in conjunction with the 
psychosocial interventions of medication management, group 
therapy, case management and day treatment. 
Patient resided in a supervised apartment where 
medication was monitored daily to ensure compliance. Patient 
also attended group therapy weekly where the focus of 
discussion was on identifying symptoms of illness and 
stressors that precipitated the manifestation of symptoms and 
how to redirect thoughts and focus when experiencing 
dysfunctional stimulus (delusions and/or auditory and/or 
visual hallucinations). Patient had a case manager that made 
contact with her weekly to assess functioning in her living 
environment. Patient worked four hours daily Monday-Friday to 
provide daily structure as mandated by residential program. 
As required by the research protocol, the patient was 
seen at Emory Research and Behavioral Science Program 
bimonthly, during the course of the scheduled appointments, 
the PANSS and the Quality of Life scales were administered to 
assess the presence of persistent symptoms. 
Intervention Phase 
Throughout the intervention phase, the subject received 
antipsychotic medication from Emory University's Research and 
Behavioral Science program and the psychosocial therapies 
were comprised of group therapy, case management, sheltered 
employment through day treatment at Skyland Trail, and 
medication monitoring by case manager and research team at 
Emory. 
Week Two 
On the first visit following the initial administration 
of Seroquel, patient continued to present with positive and 
negative symptoms. Patient was delusional and emotionally 
withdrawn. The research team increased her daily dosage from 
25mg BID to 50mg BID. Research clinician educated patient on 
the possible side effects associated with the medication and 
information was given on who should be contacted if symptoms 
increase or side effects are intolerable, case manager was 
present at visit and told patient that she would visit her 
weekly to monitor her compliance with medication and make 
visits to place of employment. Group therapist would report 
to the research team the level of interaction and patient's 
insight into illness. 
Week Four 
Patient presented with a noticeable improvement; 
however the drug regiment was causing her to be drowsy during 
the day. The medication schedule was modified to alleviate 
day time drowsiness. Patient was instructed to split A.M. 
dose to 25mg and increase P.M. dose to lOOmg. The regiment 
was explained to the patient. The change would prevent day 
time drowsiness and aid in sleeping at the appropriate time. 
Research team was in contact with patient’s case manager to 
assess patient's functioning in community and response to 
medication, case manager reported a visual degree of 
improvement as reflected in the assessment at the research 
site. 
Week Six 
Patient presented same as at previous visit, but no 
longer complaining of daytime sedation. In response to drug 
tolerance and room for further improvement, medication dosage 
was increased 75mg daily (50mg A.M. and 150mg P.M.). Patient 
continued all psychosocial involvement as instructed. 
Patient's positive symptoms were moderately controlled but 
negative symptoms were profoundly present. Patient's affect 
was blunt and she continued to be emotionally withdrawn. 
Therapist reported very little activity in group sessions. 
Group discussion was centered around the importance of 
medication compliance and identifying stressful situations 
that could lead to an exacerbation of symptoms. Patient's 
work activity was satisfactory, for she was permitted to work 
alone. Her duties were to answer the telephone and take 
messages for a small business four hours a day. 
Week Eight 
Patient was verbally expressive of how much better she 
was feeling. She stated that the last two weeks had been 
enjoyable. She reported that she had gone shopping and out 
to eat with two other residents. Case manager reported that 
patient had greatly improved. Her affect was brighter; 
thoughts were clearer and therapist stated she was an active 
participant in the group sessions. She was very verbal in 
group session and initiated conversation with several 
residents. Dosage was increased to 200mg daily. 
Week Ten 
Patient continued to be functioning well with positive 
symptoms controlled and negative symptoms diminishing, case 
manager continued to follow patient in community to ensure 
stability. 
Week Twelve 
Patient reported with an increase in positive symptoms. 
She had paranoid delusions, thinking that she was going to be 
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evicted from her apartment and lose her job. Patient felt 
that others had the capability of hearing her thoughts. Case 
manager reported that patient had missed taking 5 days of her 
medication. Research team stressed the importance of 
compliance with the patient. The clinician told the patient 
that it was not uncommon for patients when they feel better 
not to take their medication, because they do not think they 
need it any longer. Patient was then educated on the illness 
and how symptoms subside in the presence of treatment, 
though the illness had not dissipated. Patient's supervisor 
at work site contacted case manager to voice concern. 
Patient had been hostile at work and messages were not 
legible. Dose was continued at 200 mg daily. 
Week Fourteen 
Patient reported doing much better. A return to 
previous functioning, before noncompliance, case manager 
visited patient twice weekly as opposed to once a week during 
this visit interval because of increased symptoms. 
Week Sixteen 
Patient reported with bright affect, pleasant mood and 
appropriate thought and speech content, case manager 
reported patient functioning at highest level since she 
entered the program. Dose continued at 200mg daily. 
Week Eighteen 
Patient reported to visit with bright affect and mood as 
previously noted. Patient continues to participate in group 
and a sheltered work program. Patient has made notable 
improvement but still has room for further enhancement. 
Delusions are less profound and social initiatives are more 
evident but with some impairment. 
Week 20 and 24 
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Patient's level of functioning continues as previously 
noted. Schizophrenic patient's benefit from multiple 
services. To ensure stability in the community, patients need 
someone that monitors them periodically to make sure that 
they are taking their medications as prescribed, attending 
all medical and psychiatric appointments and have structured 
daily activities. If these patients are allowed to sit idle, 
they will totally diminish. For the subject in this study, 
case management was a vital part of the psychosocial 
intervention. 
CHAPTER 4 
PRESENTATION OF FINDINGS 
An AB Design was employed to evaluate the effectiveness 
of an integrated treatment approach (psychopharmacologic and 
psychosocial intervention) on a patient with schizophrenia. 
The baseline was contrived from information obtained by a 
research clinician prior to the subject entering the research 
protocol. Intervention phase, period of treatment, consisted 
of seven data collection points. To assess the overall 
progression of the subject, two standardized scales were 
used. (1) Positive and Negative Syndrome Scale (PANSS), (2) 
The Quality of Life Scale. These scales were utilized for 
their ability to clearly and succinctly tap the symptoms of 
the illness that infringe upon the quality of life for the 
schizophrenic population. The baseline was compared to the 
intervention phase to evaluate the effectiveness of the 
integrative approach. 
To compute the observed data two statistical tests were 
utilized. In analyzing the scores of the PANSS, a t-score 
was obtained. To analyze the scores of the Quality of Life 
the standard deviation from the mean was ascertained. The 
study proposed that the integrative treatment approach of 
psychopharmacologic and psychosocial treatment would have a 
positive effect on the quality of life for a schizophrenic 
patient. 
During the baseline phase (Week 0), the mean of the 
Quality of Life on a 6 point scale, measured at 2 with a 
standard deviation of 1.18. PANSS scores for baseline were 
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plotted on the PANSS profile form to obtain the percentile of 
patients level of positive and negative symptoms and a 
t-score. T-score for positive symptoms was 50 and T- score 
for negative symptoms was 62. 
The data computed from week 24, last week of the phase 
on the Quality of Life Scale showed a mean of 3.62 on a 6 
point scale with a standard deviation of .58. The T- score 
rating for the PANSS during this last week of intervention 
was at 34 for positive symptoms and 44 for negative symptoms. 
The data presented shows that the integrated treatment 
approach of pharmacologic and psychosocial interventions did 
have a positive effect on the quality of life for the 
schizophrenic patient. The Quality of Life scores from Week 
0 and Week 24 of intervention were compared showing a 
definite increase in the quality of life for the subject(see 
Figure 1). The graph gives a visual account of the degree of 
improvement and lessening of positive and negative symptoms 
using the PANSS(see Figure 2). 
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Figure 2. Baseline and Week 24 of Intervention 
CHAPTER 5 
SUMMARY AND CONCLUSIONS 
Limitation of Study 
Due to the single system design, the results are not 
greatly generalizable to the entire population of 
schizophrenia patients. Also in view of the limitations, 
reviewing archival records, the chosen psychosocial 
interventions were plotted outside the control of the 
researcher. It would have been beneficial to compare various 
psychosocial approaches within the integrative treatment. 
Recommendations For Future Research 
To diligently seek the most efficacious treatment 
approach for those robbed of a life of quality by 
schizophrenia, intense research must be aimed at integrative 
approaches to alleviate all symptoms. Studies need to be 
implemented over an extended period of time to gain greater 
knowledge of the interventions that have time limited 
responses. Also there is a need to try this approach on a 
larger sample size with varying degrees of intensity and 
frequency of the interventions. 
The treatment community needs to be more supportive and 
aware of the needs of this population. Much money and effort 
goes into the marketing of new antipsychotic treatment. But 
those that benefit the most are not the patients that are 
debilitated by the disease, it is the pharmaceutical 
companies. In many instances, patients that really need 
treatment can not get it because of a lack of resources. 
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As previously stated, much money is poured into research 
for antipsychotics, by pharmaceutical companies who in return 
get a more than substantial pay off. Is this the reason for 
drug therapy being, in most instances, the only mode of 
treatment? Consequently, there are no such companies pouring 
money into researching the efficacy of psychosocial treatment 
and there is a definite need. This is the primary reason for 
psychosocial interventions being a theorized notion instead 
of an empirical reality. 
Implications for Practice 
The search for effective modes of interventions for 
schizophrenia has existed over decades, but in recent years, 
advances have been made in antipsychotic and psychosocial 
treatment. As evidence supports, the collaborative efforts 
of each modality needs to be carefully administered and 
monitored to ensure personalized care. It is pertinent for 
patients, families and clinicians to be cognizant of the fact 
that schizophrenia is a lifelong disability requiring varying 
methods of treatment to adequately meet the needs of the 
individual patient at different stages of the illness. A 
commitment to the understanding of the illness being long¬ 
term promotes realistic expectations. Being mindful of the 
treatments proposed neither approach works independently of 
the other to alleviate all the symptoms incurred by 
schizophrenia. 
With optimal treatment,however, it is conceivable that 
many individuals with this illness can regain a modest degree 
of social and occupational functioning. Treatment systems 
must ensure that care is provided continuously and without 
interruption across service settings and they should employ a 
comprehensive array of interventions. 
Implications For Social Work Practice 
As the social worker fills the role of advocate, he or 
she must work within the system to ensure that optimal and 
continuous care is given to this population. The social 
worker can use group work, psychoeducation, supportive 
therapy, and basic clarification techniques to help patients 
identify early psychotic symptoms, and side effects to 
medication. This is all in an attempt to empower the patient 
with knowledge and insight into his illness. 
In filling the role of policy practitioner, the social 
worker can work to change legislature that allows 
pharmaceutical companies to benefit from such illnesses as 
schizophrenia. These companies should have more programs 
within their structure to provide treatment free of charge to 
the indigent. 
This population still stands in the need of a banner 
carrier to eradicate the stigma associated with mental 
illness. Until mental illness is viewed like any other 
physical illness, such as diabetes, services will be less 
than desireable in most cases. 
Although, advances have been made on the national and 
state levels to empower patients and their families with some 
control over the services received in the mental health 
system, more needs to be done to optimize care for the 
mentally ill. With Senate Bill 100 and the establishment of 
community service boards, which are chaired by patients, 
family members and advocates, many patients are being heard 
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and their needs being addressed. But, what about those that 
are not cognitively intact and have burned bridges with 
family and community agencies. For these, there needs to be 
a voice crying out from the wilderness. 
Appendix 
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Positive and Negative Syndrome Scale (PANSS) 
1=Absent 2=Minimal 3=Mild 4=Moderate 
5=Moderate severe 6=Severe 7=Extreme 
PI. Delusions 1 2 3 4 5 6 7 
P2. Conceptual disorganization 1 2 3 4 5 6 7 
P3. Hallucinatory behavior 1 2 3 4 5 6 7 
P4. Excitement 1 2 3 4 5 6 7 
P5. Grandiosity 1 2 3 4 5 6 7 
P6. Suspiciousness/ persecution 1 2 3 4 5 6 7 
P7.Hostility 1 2 3 4 5 6 7 
N1. Blunted Affect 1 2 3 4 5 6 7 
N2. Emotional withdrawal 1 2 3 4 5 6 7 
N3. Poor rapport 1 2 3 4 5 6 7 
N4. Passive/apathetic social withdrawal 1 2 3 4 5 6 7 
N5. Difficulty in abstract thinkinq 1 2 3 4 5 6 7 
N6. Lack of spontaneity and flow of conversation 1 2 3 4 5 6 7 
N7. Stereotyped thinking 1 2 3 4 5 6 7 
G1. Somatic concern 1 2 3 4 5 6 7 
G2. Anxiety 1 2 3 4 5 6 7 
G3. Guilt feelings 1 2 3 4 5 6 7 
G4. Tension 1 2 3 4 5 6 7 
G5. Mannerisms and posturing 1 2 3 4 5 6 7 
G6. Depression 1 2 3 4 5 6 7 
G7. Motor retardation 1 2 3 4 5 6 7 
G8. Uncooperativeness 1 2 3 4 5 6 7 
G9. Unusual thouqht content 1 2 3 4 5 6 7 
G10. Disorientation 1 2 3 4 5 6 7 
G11. Poor attention 1 2 3 4 5 6 7 
G12. Lack of judgment and insight 1 2 3 4 5 6 7 
G13. Disturbance of volition 1 2 3 4 5 6 7 
G14. Poor impulse control 1 2 3 4 5 6 7 
G1 5. Preoccupation 1 2 3 4 5 6 7 
G16. Active social avoidance 1 2 3 4 5 6 7 
QUALITLY OF LIFE SCALE 
0=Totally deficient 6=Without impairment 
1. relationship with household members 0 i 2 3 4 5 6 
2.intimate relationship 0 i 2 3 4 5 6 
3.active acquaintances 0 i 2 3 4 5 6 
4.social activity 0 i 2 3 4 5 6 
5.social network 0 i 2 3 4 5 6 
6. social initiatives 0 i 2 3 4 5 6 
7. social withdrawal 0 1 2 3 4 5 6 
8. sociosexual relations 0 i 2 3 4 5 6 
9. occupational role function 0 i 2 3 4 5 6 
10. level of accomplishment 0 i 2 3 4 5 6 
11 .degree of underemployment 0 i 2 3 4 5 6 
12. satisfaction with occupational role 0 i 2 3 4 5 6 
'13. sense of puipose 0 i 2 3 4 5 6 
14. degree of motivation 0 i 2 3 4 5 6 
1 5. curiosity 0 i 2 3 4 5 6 
16. anhedonia 0 i 2 3 4 5 6 
1 7. time utilization 0 1 2 3 4 5 6 
18. commonplace objects 0 1 2 3 4 5 6 
19. commonplace activities 0 1 2 3 4 5 6 
20. capacity for empathy 0 i 2 3 4 5 6 
21. capacity for engagement with interviewer 0 i 2 3 4 5 6 
T 
GOAL ATTAINMENT SCALE 
Levels of Patient Patient's Patient Patient Patient 
Predicted Attends Medication Initiates Identifies Utilizes 
Attainment Group 
Sessions 
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